Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN10018 + cobimetinib
- Development stage
- Unknown
- Lead developer
- InxMed (Shanghai) Co., Ltd.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**IN10018 + cobimetinib** is an investigational combination therapy undergoing clinical trials primarily in metastatic uveal melanoma and NRAS-mutant metastatic melanoma. IN10018 (BI853520) is a potent, highly selective, ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor owned by InxMed, designed to modulate the tumor microenvironment, overcome fibrosis/immune tolerance, and synergize with other therapies including targeted agents, chemotherapy, immunotherapy, and radiation. Cobimetinib (Cotellic) is an orally available, selective inhibitor of MEK1, a component of the MAPK/ERK pathway, developed and marketed by Roche. The combination aims to target tumor growth and survival both via direct antitumor activity (through FAK/MEK pathway inhibition) and by modifying the tumor microenvironment to enhance responsiveness to treatment[3][4][5][6].
- Brand names
- Cotellic
- Other names
- IN10018 + CotellicBI853520 + cobimetinib
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on IN10018 + cobimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN10018 + cobimetinib.